Cognition Therapeutics, Inc. (CGTX)

NCM – Real Time Price. Currency in USD

1.05

+0.03 (2.93%)

Market open: Aug 12, 2026, 2:55 PM EDT

1.01

-0.01 (-0.93%)

Previous after-hours: Aug 11, 2026, 7:39 PM EDT

07.08.2026

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics, Inc. (CGTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.11 per share a year ago.

06.08.2026

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Cognition Therapeutics, Inc. (CGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cognition Therapeutics, Inc. (CGTX)

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Search stocks

Cognition Therapeutics, Inc. (CGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cognition Therapeutics, Inc. (CGTX)

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update